[Federal Register Volume 86, Number 191 (Wednesday, October 6, 2021)]
[Notices]
[Page 55625]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-21845]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Personalized 
Tumor Vaccine and Use Thereof for Cancer Immunotherapy

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the (U.S.) Patents and Patent Applications 
listed in the Supplementary Information section of this notice to NE1 
Inc, located at 515 Madison Avenue, 8th Fl. Suite 8096, New York, NY 
10022.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before October 21, 2021 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Dr. Berna Uygur, Technology Transfer Manager, 
NCI Technology Transfer Center, Telephone: (240)-276-5530; Email: 
[email protected].

SUPPLEMENTARY INFORMATION:

Intellectual Property

    (United States Provisional) Patent Application No. 62/946,934, 
filed on December 11, 2019 and entitled ``Personalized Tumor Vaccine 
and Use Thereof for Cancer Immunotherapy'' [HHS Reference No. E-003-
2020/0-US-01]. (PCT) Patent Application No. PCT/US2020/064412, filed on 
December 11, 2020 and entitled ``Personalized Tumor Vaccine and Use 
Thereof for Cancer Immunotherapy'' [HHS Reference No. E-003-2020/0-PCT-
02].
    The patent rights in this invention are co-owned by (a) the United 
States of America, as represented by the Secretary, Department of 
Health and Human Services, (b) University of South Bohemia, and (c) NE1 
Inc. The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to: Development, manufacture, and 
commercialization of the MBTA Therapy Products, as claimed in the 
Licensed Patent Rights, for the treatment of cancer in humans.
    This technology discloses ``MBTA Therapy Product(s)'' which are 
vaccine products comprising irradiated tumor cells pulsed with 
phagocytic agonists (Mannan-BAM, a polysaccharide derivative of 
mannan), TLR (Toll-like receptor) ligands, and Anti-CD40-monoclonal 
antibody. The MBTA Therapy Products may be used as personalized tumor 
vaccines to treat cancer.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: October 1, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2021-21845 Filed 10-5-21; 8:45 am]
BILLING CODE 4140-01-P